Basic Information
| LncRNA/CircRNA Name | LINC00222 |
| Synonyms | NA |
| Region | GRCh38_6:108751654-108769942 |
| Ensemble | ENSG00000203801 |
| Refseq | NR_033376 |
| Regulatory Mechanism | Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Information of Cancer
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot |
| Sample | lung adenocarcinoma tissues, cell lines (SPC-A-1 and LTEP-a-2) |
| Expression Pattern | down-regulated |
| Function Description | We investigated expression of the lncRNA LINC00222 in 76 lung adenocarcinoma tissues and paired normal lung tissues and found that LINC00222 is downregulated in lung adenocarcinoma tissues. Enforced expression of LINC00222 significantly inhibited the proliferation, migration and invasive ability of lung adenocarcinoma cells, and also induced apoptosis. Kaplan-Meier survival analysis was performed to investigate the correla-tion between LINC00222 expression and patient prognosis in terms of disease-free survival (DFS) and overall survival (OS). Patients in thelow LINC00222 group had a higher recurrence rate (median DFS of 16months) and much shorter overall survival (median OS of 21 months)than those in the high expression group (median DFS of 26 months;median OS of 31 months; P = 0.0294 and 0.0177, respectively). Furthermore, overexpression of LINC00222 enhanced the activity of glycogen synthase kinase-3? (GSK3?), which is a key element of the Wnt signaling pathway. |
| Pubmed ID | 29990868 |
| Year | 2018 |
| Title | Long Non-Coding RNA LINC00222 Regulates GSK3? Activity and Promotes Cell Apoptosis in Lung Adenocarcinoma |
External Links
| Links for LINC00222 | GenBank HGNC Noncode |
| Links for lung adenocarcinoma | Omim Cosmic |